Publications by authors named "Steven L Highfill"

Claim this Profile
1
10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemia.
Alexandra Dreyzin, Bonnie Yates, Haneen N Shalabi, Sara K Silbert, Hao-Wei Wang, Steven L Highfill

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the impact of cell isolation method on B cell gene expression using next-generation sequencing.
Amanda N Henning, Jordan Pardoe, Darryl Owusu-Ansah, Hong Lei, Kobe Robichaux, Steven L Highfill

Exp Hematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.
Hasmukh Jain, Atharva Karulkar, Devanshi Kalra, Smrithi Ravikumar, Shreshtha Shah, Steven L Highfill

Lancet Haematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy.
Roshini Traynor, Isabella Vignola, Sarmila Sarkar, Michaela Prochazkova, Yihua Cai, Steven L Highfill

Cytotherapy· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR-T cell expansion platforms yield distinct T cell differentiation states.
Hannah W Song, Michaela Prochazkova, Lipei Shao, Roshini Traynor, Sarah Underwood, Steven L Highfill

Cytotherapy· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function.
Sarah Underwood, Jianjian Jin, Lipei Shao, Michaela Prochazkova, Rongye Shi, Steven L Highfill

Immunohorizons· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.
Meijie Tian, Jun S Wei, Nityashree Shivaprasad, Steven L Highfill, Berkley E Gryder

Cell Rep Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering the importance of culture pH on CD22 CAR T-cells characteristics.
Michaela Prochazkova, Alexandra Dreyzin, Lipei Shao, Pam Garces, Yihua Cai, Steven L Highfill

J Transl Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output.
Hannah W Song, Mehdi Benzaoui, Alka Dwivedi, Sarah Underwood, Lipei Shao, Steven L Highfill

Mol Ther Methods Clin Dev· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia.
Christina Amatya, Katherine A Weissler, Vicki Fellowes, Norris Lam, Lauren C Cutmore, Steven L Highfill

Mol Ther Methods Clin Dev· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.
Jennifer N Brudno, Danielle A Natrakul, Jeremiah Karrs, Nisha Patel, Roberto Maass-Moreno, Steven L Highfill

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment and comparison of viability assays for cellular products.
Yihua Cai, Michaela Prochazkova, Yong-Soo Kim, Chunjie Jiang, Jinxia Ma, Steven L Highfill

Cytotherapy· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain.
Lekha Mikkilineni, Danielle A Natrakul, Norris Lam, Elisabet E Manasanch, Jennifer Mann, Steven L Highfill

Mol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.
Sabina Kaczanowska, Tara Murty, Ahmad Alimadadi, Cristina F Contreras, Caroline Duault, Steven L Highfill

Cancer Cell· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.
Meijie Tian, Jun S Wei, Nityashree Shivaprasad, Steven L Highfill, Berkley E Gryder

Cell Rep Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reference gene selection for clinical chimeric antigen receptor T-cell product vector copy number assays.
Jinxia Ma, Lipei Shao, Tatyana Fuksenko, Hui Liu, Rongye Shi, Steven L Highfill

Cytotherapy· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing a fully automated and closed system process for red blood cell reduction of human bone marrow products.
Victoria Ann Remley, Ashley Collins, Sarah Underwood, Jianjian Jin, Yoon Kim, Steven L Highfill

Cytotherapy· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells.
Alexandra Dreyzin, Sandhya R Panch, Haneen Shalabi, Bonnie Yates, Steven L Highfill

Mol Ther Methods Clin Dev· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
Daniel S Green, Franklin Ning, Anna Duemler, Timothy G Myers, Kathryn Trewhitt, Steven L Highfill

Clin Cancer Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
Daniel S Green, Franklin Ning, Anna Duemler, Timothy G Myers, Kathryn Trewhitt, Steven L Highfill

Clin Cancer Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1.
Richard H Smith, Hanan Bloomer, Danielle Fink, Keyvan Keyvanfar, Md Nasimuzzaman, Steven L Highfill

Hum Gene Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products.
Lipei Shao, Rongye Shi, Yingdong Zhao, Hui Liu, Alexander Lu, Steven L Highfill

J Transl Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies.
Hannah W Song, Robert P Somerville, David F Stroncek, Steven L Highfill

Int Rev Immunol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Haneen Shalabi, Haiying Qin, Angela Su, Bonnie Yates, Pamela L Wolters, Steven L Highfill

Blood· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Point-of-care cell therapy manufacturing; it's not for everyone.
David F Stroncek, Robert P T Somerville, Steven L Highfill

J Transl Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis